FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Find answers to all your questions on live LALPATHLAB message board: Is LALPATHLAB buy or sell? Should I buy LALPATHLAB shares? Why are LALPATHLAB shares falling? Should I invest in LALPATHLAB stock?

forum

LALPATHLAB Share Price Discussion

Dr. Lal Path Labs Ltd.
NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Sector: Pharmaceuticals and health care
A
Reputation: 689 • Jun 19 4:59 AM


Type
Buy
Instrument
LALPATHLAB
Entry Price
₹1,535.05
Price@Trade
₹1,535.05
Target Price
₹1,680
Stop Price
₹1,450
Valid Till
Jun 18, 2021 3:20 AM
Margin
₹767,525 approx for 500 Qty
Status
Target Achieved
Exit Price
₹1,680
Net P&L
+₹72,475 (+9.44%)
Like
Reply (1)
NSE:LALPATHLAB price when posted: 1,535.05
1 Replies
TrackerBot @trackerbot
Jul 6 2:53 AM

Update
Target Achieved
Exit Price
₹1,680
Recent posts in LALPATHLAB

Type
Sell
Instrument
LALPATHLAB
Entry Price
₹1,880
Price@Trade
₹1,879.05
Target Price
₹1,800
Stop Price
₹1,950  ₹1,880
Valid Till
Aug 3, 2020 3:20 AM
Margin
₹752,000 approx for 400 Qty
Status
Exited
Exit Price
₹1,852
Net P&L
+₹11,200 (+1.49%)
Like
Reply (3)
D
Reputation: 21,340 • Today 5:00 AM

Prabhudas Lilladher target on LALPATHLAB
Date: 03-Aug-20 Broker: Prabhudas Lilladher Price @ Call: 1888.85 Target: 1006 Recommendation: SELL
Like
Reply
N
Reputation: 4,641 • Jul 31 9:56 AM
Dr Lal PathLabs Q1 results: Net profit declines 52% to Rs 28.4 crore
The company had posted a net profit of Rs 59.1 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing to BSE.
The Economic Times
Like
Reply
N
Reputation: 4,641 • Jul 31 8:43 AM
Dr Lal PathLabs Q1 profit falls 52% to Rs 28.4 crore
Its revenue was down 20.6% at Rs 266 crore against Rs 335.2 crore.
Moneycontrol
Like
Reply
N
Reputation: 4,641 • Jul 23 4:46 AM
Pick up these 5 pharma stocks in August: Sanjiv Bhasin
Pharma is in for profit booking for the next week or so, but August will again belong to most of the large cap pharma stocks.
The Economic Times
Like
Reply
N
Reputation: 4,641 • Jul 15 7:38 AM
Dr Lal PathLabs shares hit fresh all-time high; analysts positive on firm's long term story
Despite the turmoil caused by COVID-19, the stock has been gaining significantly in the calendar year 2020 so far. The stock has gained 27 percent as of July 14 close on BSE against a 13 percent fall in benchmark Sensex.
Moneycontrol
Like
Reply